參展商

AD Check 認知測™ uses a breakthrough medical technology that has been clinically validated and recognized by the U.S. Food and Drug Administration (FDA) to accurately detect the levels of a biomarker related to Alzheimer’s Disease (AD) pathology in the blood: phosphorylated Tau217 protein (p-Tau217). This helps assess the risk of Alzheimer’s Disease (AD) pathology and allows for regular monitoring of risk changes as individuals age.Research further indicates that the testing technology used in AD Check 認知測™ is consistent with the results of traditional positron emission tomography (PET-Aβ, PET-Tau) and cerebrospinal fluid biomarkers (CSF Aβ42/40, and CSF p-Tau181).AD Check認知測™ accuracy reaches 96%, with a sensitivity of 98.2% and a specificity of 98.6%,test by local accredited laboratory.

Virtual Brain Technology (Free On-Site Trials Available May 16-18)Virtual Brain is the only product in Hong Kong that utilizes eye-tracking technology to accurately screen for the risk of brain degeneration and incorporates virtual reality technology for targeted brain degeneration therapy. This innovative smart product has been certified by the U.S. FDA and China's NMPA and is used as a medical-grade screening and treatment product. The virtual reality device automatically tracks eye movement trajectories, requiring no physical action from the user, and completes the screening in just 5 minutes. It can easily identify risks of mild cognitive impairment (MCI) and dementia with an accuracy rate of 78% - 91%. After the screening, AI automatically analyzes data from six cognitive areas of the user and recommends a tailored list of virtual reality game therapies. During the game therapy, AI analyzes user data and adjusts the difficulty in real-time, customizing it to achieve optimal training results.SMART solution for occupational therapy centers, community rehabilitation centers, and nursing homes.For more information, please contact:(852) 9711 9922

Discover Early Risks of Mild Cognitive Impairment (MCI) and Seize Early Treatment Opportunities to Delay Disease ProgressionBDR Technology Overview (Free On-Site Trials Available May 16-18)Electroencephalography (EEG) signals are one of the effective tools for diagnosing brain disorders. The BDR system is FDA approved in the United States and utilizes a 5-minute EEG collection followed by AI analysis to calculate the probabilities of normal and mild brain degeneration, continuously monitoring degenerative trends. This technology offers a non-invasive, convenient, safe screening process with clinical data validation, achieving an accuracy rate of 84%. BDR has successfully overcome the challenges of traditional methods in identifying early brain degeneration, representing an innovative application of medical technology in early screening. [2] Wijaya A, Setiawan NA, Ahmad AH, Zakaria R, Othman Z. Electroencephalography and mild cognitive impairment research: A scoping review and bibliometric analysis (ScoRBA). AIMS Neurosci. 2023 Jun 13;10(2):154-171. doi: 10.3934/Neuroscience.2023012. PMID: 37426780; PMCID: PMC10323261. Achieve Early and Accurate Assessment of Brain Degeneration Risk to Delay and Prevent Ongoing Deterioration!SMART solution for use by medical institutions and elderly care service organizations. For more information, please contact:(852) 9711 9922

Accurate, Objective Depression Risk Assessment,&nbsp;Effectively Assisting&nbsp;Clinical Psychological TreatmentSEA Technology Introduction (Free On-Site Trials Available May 16-18)The SEA system is the world's first system to analyze brainwave stress indices. This system is FDA approved in the US and utilizes a 5-minute collection of brain signals followed by AI analysis. It provides objective data assessment beyond self-perception and behavioral observation, displaying an intuitive stress data distribution chart to assist in discovering latent depression. This technology offers a non-invasive, convenient, safe screening process with clinical data validation, achieving an accuracy rate of 84%. It can assist experts or patients themselves in screening and monitoring conditions for treatment reference, complementing traditional diagnostic methods with meaningful innovative intelligent testing data. SMART solution for use by mental health communities/counseling centers and medical institutions.For more information, please contact:(852) 97119922

展會概覽

參展商名單

產品目錄

展覽廳切面圖

成功故事

重要公佈

展會資訊

申請展位

參展費用及形式

廣告服務

中小企業市場推廣基金

資訊中心

參展資訊

網上預先登記

電子通訊

香港貿發局商貿平台APP及e-Badge

訪客規則及法規

請小心處理由第三者提供之推廣優惠

參觀資訊

新聞稿

照片廊

展覽視頻

社交媒體/網絡動態

合作媒體

新聞中心

傳媒資訊

活動

香港的旅遊簽證和入境規例

辦理中國內地入境簽證及安排行程

特惠酒店

特惠機票

餐飲優惠

香港機場管理局提供專屬優惠

香港跨境現金管制措施

前往會場

Information for Muslim Visitors

暢遊香港

惡劣天氣的安排

訪港資訊

查詢

常見問題

貿發局活動

展會場刊 2025

合作媒體 2025

額外設施及服務申請表格

參展商手冊

初次參展須知

參展費用及形式 2026

主頁

通告

國泰航空機票優惠

與會人士快速過關安排

聯繫我們

綠色小貼士

穿梭巴士

衞生措施及健康資訊

社交媒體/網絡動態 - 2021

社交媒體/網絡動態 - 2019

社交媒體/網絡動態 - 2018

社交媒體/網絡動態- 2017

社交媒體/網絡動態 - 2016

Virtual Booths

Press Release

Agenda

研討會及論壇

保健護理世界

保健護理世界 - 一般資料

保健護理世界 - 聯繫我們

保健護理世界 - 概覽

保健護理世界 - 展品類別介紹

社交媒體/網絡動態 - 2022

展會資料下載

重要通告 (一)

社交媒體/網絡動態 - 2024

Information for Muslim Visitors (只提供英文版本)